PT - JOURNAL ARTICLE AU - Salvatore, Maxwell AU - Gu, Tian AU - Mack, Jasmine A. AU - Sankar, Swaraaj Prabhu AU - Patil, Snehal AU - Valley, Thomas S. AU - Singh, Karandeep AU - Nallamothu, Brahmajee K. AU - Kheterpal, Sachin AU - Lisabeth, Lynda AU - Fritsche, Lars G. AU - Mukherjee, Bhramar TI - A phenome-wide association study (PheWAS) of COVID-19 outcomes by race using the electronic health records data in Michigan Medicine AID - 10.1101/2020.06.29.20141564 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.29.20141564 4099 - http://medrxiv.org/content/early/2020/07/01/2020.06.29.20141564.short 4100 - http://medrxiv.org/content/early/2020/07/01/2020.06.29.20141564.full AB - Blacks/African Americans are overrepresented in the number of hospitalizations and deaths from COVID-19 in the United States, which could be explained through differences in prevalence of existing comorbidities. We performed a disease-disease phenome-wide association study (PheWAS) using data representing 5,698 COVID-19 patients from a large academic medical center, stratified by race. We explore the association of 1,043 pre-occurring conditions with several COVID-19 outcomes: testing positive, hospitalization, ICU admission, and mortality. Obesity, iron deficiency anemia and type II diabetes were associated with susceptibility in the full cohort, while ill-defined descriptions/complications of heart disease and stage III chronic kidney disease were associated among non-Hispanic White (NHW) and non-Hispanic Black/African American (NHAA) patients, respectively. The top phenotype hits in the full, NHW, and NHAA cohorts for hospitalization were acute renal failure, hypertension, and insufficiency/arrest respiratory failure, respectively. Suggestive relationships between respiratory issues and COVID-19-related ICU admission and mortality were observed, while circulatory system diseases showed stronger association in NHAA patients. We were able to replicate some known comorbidities related to COVID-19 outcomes while discovering potentially unknown associations, such as endocrine/metabolic conditions related to hospitalization and mental disorders related to mortality, for future validation. We provide interactive PheWAS visualization for broader exploration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the University of Michigan Precision Health Initiative, University of Michigan Rogel Cancer Center, Michigan Institute of Data Science, NSF DMS 1712933 and NIH NCI P30 CA 046592-30-S3.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols were reviewed and approved by the University of Michigan Medical School Institutional Review Board (IRB ID HUM00180294 and HUM00155849).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared publicly due to patient confidentiality. The data underlying the results presented in the study are available from University of Michigan Data Office for Clinical & Translational Research for researchers who meet the criteria for access to confidential data.